Clinical Trials
26 trialsNCT06321640 2024-03-20
POSITive
European Institute of Oncology
Unknown
NCT06307093 2024-03-12
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
Phase 1 Unknown
NCT04544748 2024-03-06
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
AO GENERIUM
Phase 1 Unknown
NCT03840928 2023-12-13
PatientSpot Formerly Known as ArthritisPower
Global Healthy Living Foundation
Unknown
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT03313544 2023-04-21
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Assistance Publique Hopitaux De Marseille
Phase 4 Unknown
NCT04821570 2023-04-04
CANINE
University of Kansas Medical Center
Unknown
NCT05156515 2023-03-29
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT00986661 2022-11-02
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
Phase 1 Unknown
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT03934827 2022-08-11
MICROBIOME
Imperial College London
Phase 1 Unknown
NCT05230186 2022-02-09
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
TScan Therapeutics, Inc.
Unknown
NCT05180851 2022-02-01
YSCH-01
Shanghai Fengxian District Central Hospital
Phase EARLY_PHASE1 Unknown
NCT05190185 2022-01-13
A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT04929353 2021-06-18
IRMA
University Of Perugia
Phase NA Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT04268368 2020-02-17
ICI-DISCOVER
Università Politecnica delle Marche
Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT04001725 2019-11-13
OPTIMAL
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02861209 2019-04-16
CONTACT
KU Leuven
Phase NA Unknown
NCT03050047 2018-08-31
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
Biocad
Phase 1 Unknown
NCT02457650 2016-08-03
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT00324597 2013-09-17
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT01584115 2012-04-25
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
Instituto de Investigação em Imunologia
Phase 1/2 Unknown